Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses final analysis data from a phase 2 study that evaluated fedratinib in myelodysplastic syndromes/myeloproliferative neoplasms overlap syndrome. The therapy has also been evlauated in and chronic neutrophilic leukemia.
The endpoints of the investigator-initiated trial include progression-free survival, overall survival, and duration of response.
The results showed a 30% spleen response rate and a 47% symptom response rate among evaluable patients. Overall survival reached around 37 months, according to the 2026 ASCO abstract.
Reference
Kuykendall A. A phase 2 study of fedratinib in patients with MDS/MPN and chronic neutrophilic leukemia. 2026 ASCO Annual Meeting. Chicago; May 29 to June 2, 2026.
Leave feedback about this